Humana Inc (HUM)

Rating: SELL

STRONG SELL (5-tier) · high-risk optionality · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -44% vs spot
• Monte Carlo median implies -52% vs spot
• DCF fair value implies -21% vs spot
• Bear case (Structural — Medicare/Medicaid Reform / MLR Squeeze) downside is -75% vs spot
• Net: reward/risk of 0.5× warrants a Sell.

Investment Thesis

At $397.22 against roughly $11 of mid-cycle earnings power, spot prices Humana on a forward multiple well above its managed-care peers, implying the market believes the current benefit-ratio pressure is transient and that Medicare Advantage margins normalise quickly. The engine disputes that. Our Base path carries a ~1.2% pre-tax margin and a 20x multiple for a $227 anchor, and the probability-weighted target of $218 sits 45% below spot. The gap is driven by the multiple: the peer-median forward P/E near 18x, set against the subject's 44x, is the load-bearing datum. Weighting a 20% structural-impairment case at $96, below the 52-week low of $161.9, alongside a 17% cost-trend case, pulls the blend down and supports the SELL rating and the $218 probability-weighted target. The single most damaging risk to that call is a faster-than-modelled MLR recovery: managed-care margins are mean-reverting, and one clean bid cycle plus a Star Ratings rebound could restore the earnings the current multiple already assumes.

The dashboard below is the whole argument on one page: spot ($395) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear mechanism is the cost-trend squeeze, not an outright reform shock. Medical-cost trend has repeatedly run ahead of the rates Humana priced, holding the insurance benefit ratio elevated and compressing an already thin pre-tax margin. Star Ratings slippage strips quality-bonus revenue at the same time, so the rate side weakens just as utilisation climbs. Bid discipline then forces plan exits, and membership growth, the engine that scales premium, stalls or reverses. Because the margin base is so slender, a one-to-two-point move in the benefit ratio swings earnings hard, and the market's premium multiple leaves no cushion. Under that path earnings sit near the mid-$8 EPS the Cost-Trend scenario models and the multiple de-rates toward the peer line.

Key Debate

Gross Margin explains 90% of Monte Carlo outcome variance — the single variable that decides which side is right.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.29 vs analyst floor +0.00 → delta +0.29 (n=25 mgmt / 13 Q&A; 32th pctile across the S&P book, z -0.6).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1000 articles): avg ticker sentiment +0.12 (bullish 19% / bearish 7%)

Scenario Analysis

The tree runs from a structural 'Structural — Medicare/Medicaid Reform / MLR Squeeze' downside ($97) to a 'Bull — Margin Recovery / Re-Rate' bull case ($401); the probability-weighted blend (PWEV $223) is -44% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Medicare/Medicaid Reform / MLR Squeeze (20%, $97). Structural impairment — Medicare/Medicaid reform / MLR squeeze: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 96.1; probability: 0.2.
• Cost-Trend Spike / Rate Inadequacy (17%, $156). Cyclical downturn — membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy weakens for 1–2 years before normalising. Drivers — implied_target: 163.19; probability: 0.17.
• Base — Membership + Premium Growth (35%, $228). Mid-cycle — normalised membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy; disciplined capital allocation; steady returns. Drivers — implied_target: 226.65; probability: 0.35.
• Growth — MA / Care-Services (Optum-style) (20%, $325). Upside — MA + care-services growth lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 305.98; probability: 0.2.
• Bull — Margin Recovery / Re-Rate (8%, $401). Upside tail — sustained tight conditions or a structural re-rate on MA + care-services growth. Drivers — implied_target: 386.44; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $188 and 19% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (90% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 20x terminal FCF multiple → $311. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 18.285x) implies $166. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 793% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Payers Providers

This name sits in the Health Payers Providers as a managed_care. membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: UNH (managed_care) · CVS (managed_care) · HCA (providers) · ELV (managed_care) · CI (managed_care) · HUM (managed_care) · CNC (managed_care) · DVA (providers) · UHS (providers)

Mapping note: name-level 'Structural — Medicare/Medicaid Reform / MLR Squeeze' (20%) + 'Cost-Trend Spike / Rate Inadequacy' (17%) map to cluster Cost-Trend Spike / Reimbursement-Reform Squeeze (37%); name-level 'Growth — MA / Care-Services (Optum-style)' (20%) + 'Bull — Margin Recovery / Re-Rate' (8%) map to cluster Upside — Margin Recovery / Care-Services (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Cost-Trend Spike / Reimbursement-Reform Squeeze () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_payers_providers cycle is the shared macro driver. Driver — medical-cost trend (MLR) + utilization + reimbursement/regulation Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 2% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $10B + PV(terminal) $37B = EV $47B; + net cash → equity $38B ÷ diluted shares 0.12B = $311/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $266/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 19% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $166; EV/Rev → $1,932.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Managed Care / Health Services multiple (AI re-rating) (base 24x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 0.2% of revenue; cash conversion (OCF/NI) 77% — earnings not cash-backed.

Catalyst Calendar

• 2026-04-06 (~-93d) — CMS 2027 MA final rate notice (authored)
• 2026-06-03 (~-35d) — Investor day — MA margin-recovery multi-year targets (authored)
• 2026-07-29 (~21d) — Quarterly earnings — est. EPS $6.17 (AV EARNINGS_CALENDAR)
• 2026-10-01 (~85d) — 2027 Stars-rating release (bonus-year impact) (authored)
• 2027-01-01 (~177d) — 2027 MA plan-year membership / benefit-design reset (authored)

Forecast Track Record

• EPS surprise: beat 87.5% of the last 8 quarters; average surprise +9.3%.

Competitive Moat

Narrow moat. Humana's edge is Medicare Advantage scale, Stars-rating economics and CenterWell care-delivery integration, but MA is a regulated, rate-taking business; a narrow moat justifies roughly the managed-care peer ~18x, and given current benefit-ratio pressure the terminal multiple cannot sustain the ~44x spot embeds — falsifiable if MA margins fail to normalize toward target, forcing compression toward or below the peer median.

Moat sources:

• #2 Medicare Advantage scale and member density (regional cost advantage)
• Stars-rating quality bonuses driving reimbursement (currently impaired)
• CenterWell/primary-care & pharmacy vertical integration lowering medical cost
• No control over CMS rates or medical-cost trend (regulated price-taker — weak moat)

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 25.1× forward EPS, vs the house DCF terminal 20.0×, and a peer median 18.285×. The house DCF sits 21% below spot, so the market is pricing in more than the house case — roughly 2.0pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 27.5× (simple median 18.285×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $162–$380, centre $248 (-37% vs spot); spot sits at the 107th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Margin Recovery / Re-Rate): $401.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (1175.0); Revenue CAGR ±3pp (101.0); Terminal × ±15% (91.0); WACC ±1pp (32.0); Capex intensity ±15% (27.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 20×, FY+5 revenue $185B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Insurance-segment benefit ratio (MLR) >= 0.905 (2 consecutive prints → Cost-Trend Spike / Reimbursement-Reform Squeeze). A benefit ratio held at or above ~90.5% signals medical-cost trend running ahead of priced rates, pinning the pre-tax margin below the mid-cycle path assumed in the Base scenario.
• Individual Medicare Advantage membership (year-on-year) < 0.0 (2 consecutive prints → Cost-Trend Spike / Reimbursement-Reform Squeeze). MA is the earnings engine; a sustained contraction in individual MA lives, driven by bid discipline or exits, undercuts the membership growth the Base and Growth paths require.
• Star Ratings share of members in 4-plus star plans (payment year) < 0.25 (single event → Cost-Trend Spike / Reimbursement-Reform Squeeze). Quality-bonus revenue hinges on Star Ratings; a payment-year cohort with under a quarter of members in 4-plus star plans removes a rate tailwind and hardens the reimbursement-squeeze mechanism.
• Adjusted EPS versus prior full-year guidance midpoint < 0.9 (single event → Mid-Cycle — Membership & Volume Growth). A full-year adjusted EPS landing below 90% of the guided midpoint would mark the Base earnings path as too optimistic and pull the weighting toward the cost-trend and structural mechanisms.
• Days-claims-payable (sequential) < 44.0 (2 consecutive prints → Cost-Trend Spike / Reimbursement-Reform Squeeze). A falling days-claims-payable balance can flag reserve inadequacy against an accelerating cost trend, raising the risk of adverse development that would validate the Cost-Trend path.

Fact / Inference / Speculation

• FACT: Spot $395; 52-week range $162–$380; engine rating SELL; base-case target $218 (-45%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $246 (-38% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Recommendation: SELL

Defensive: rating SELL; triangulated fair value $246 (-38% vs spot) — the risk/reward is skewed to the downside on Gross Margin. The debate is Gross Margin — a fundamental call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.